Brief: Aldeyra Therapeutics Receives Fast Track Designation For Adx‑2191 For The Treatment Of Retinitis Pigmentosa
19/08/2025 12:39
Aug 19 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR ADX‑2191 FOR THE TREATMENT OF RETINITIS PIGMENTOSA ALDEYRA THERAPEUTICS INC - PHASE 2/3 TRIAL OF ADX-2191 EXPECTED TO START IN 2025 Source text: ID:nBw35wRZDa Further company coverage: ALDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora